Welcome to our dedicated page for Talphera SEC filings (Ticker: tlph), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vTALPHERA, INC. CEO Vincent J. Angotti reported a routine tax-related share disposition. On April 2, 2026, he surrendered 9,938 shares of common stock at $0.7223 per share to the company to cover required tax withholdings from vesting RSUs. After this transaction, he directly holds 790,767 shares of TALPHERA common stock.
TALPHERA, INC. Chief Financial Officer Raffi Asadorian reported a routine share disposition related to taxes. On the RSU vesting date, 2,444 shares of common stock were surrendered back to the company at $0.7223 per share to cover required tax withholdings, rather than being sold on the open market. Following this tax-withholding transaction, the CFO directly holds 85,879 shares of Talphera common stock.
TALPHERA, INC. Chief Medical Officer Aslam Shakil reported a tax-withholding share disposition related to vesting restricted stock units. On this Form 4, 2,118 shares of common stock were surrendered back to the company at an effective price of $0.7223 per share to cover required tax withholdings. After this transaction, Shakil directly holds 81,060 shares of TALPHERA common stock. The filing records a compensation-related tax event rather than an open-market purchase or sale.
TALPHERA, INC. Chief Engineering Officer Badri N. Dasu reported a routine tax-related share disposition. On the RSU vesting date, 2,444 shares of common stock were surrendered back to the company at an implied price of $0.7223 per share to cover required tax withholdings, rather than being sold on the open market. After this withholding transaction, Dasu directly holds 71,440 shares of TALPHERA common stock.
Talphera, Inc. is registering for resale up to 639,931 shares of common stock and up to 6,399,316 shares issuable upon exercise of pre-funded warrants held by selling stockholders. The prospectus covers resale by those holders; the issuer will receive no proceeds from these resales.
The shares were issued in a March 31, 2025 private placement (purchase prices of $0.586 per share and $0.585 per pre-funded warrant), and the selling stockholders may sell shares from time to time through public or private transactions under various methods described in the plan of distribution. Talphera’s common stock trades on Nasdaq under the symbol TLPH; the last reported sale price shown is $0.8012 per share as of March 23, 2026. Shares outstanding were 50,049,824 as of March 16, 2026.
TALPHERA, INC. Chief Executive Officer Vincent J. Angotti purchased 213,310 shares of common stock in an open-market transaction at $0.586 per share. Following this purchase, he directly owns 800,705 common shares. Footnotes note these shares relate to the third tranche closing of a PIPE financing and that the balance includes 10,000 shares acquired through the company’s employee stock purchase plan.
Talphera, Inc. registers the resale by selling stockholders of up to 639,931 shares of common stock and up to 6,399,316 shares of common stock issuable upon exercise of pre-funded warrants.
The prospectus states these securities were issued in the Third Closing of a private placement dated March 31, 2025, and that Talphera will not receive proceeds from resales by the selling stockholders. The selling holders may sell the shares from time to time through public or private transactions; cash-flow treatment is described as proceeds to the selling stockholders. The prospectus discloses 50,049,824 shares of common stock outstanding as of March 16, 2026 and a last reported sale price of $0.8012 per share on March 23, 2026.
Talphera, Inc. filed its 2025 annual report outlining a specialty pharma business focused on hospital-based therapies, led by Niyad, a nafamostat-based regional anticoagulant for continuous renal replacement therapy.
The company reports substantial doubt about its ability to continue as a going concern and expects to incur significant losses, needing additional capital to fund operations and Niyad’s registrational trial. Niyad has FDA Breakthrough Device Designation and an ongoing Phase 3 NEPHRO CRRT study, with PMA submission planned after trial completion. Talphera also owns LTX-608 as a second nafamostat candidate and is evaluating discontinuation of its pre-filled syringe programs to prioritize nafamostat. DSUVIA was divested, with future upside tied to Department of Defense-related economics and a sale of future payments to XOMA. As of March 18, 2026, common stock outstanding was 50,049,824 shares.
Talphera, Inc. reported fourth quarter and full year 2025 results and updated progress on its NEPHRO CRRT registrational study for Niyad, a nafamostat-based anticoagulant. For Q4 2025, the company recorded no revenue and a net loss of $3.8 million, compared with a net loss of $1.9 million a year earlier. For full year 2025, revenue was $28,000 and net loss was $14.3 million versus a net loss of $13.0 million in 2024, while total operating expenses declined to about $13.5 million from $15.3 million. Cash, cash equivalents and investments were $20.4 million at December 31, 2025, up from $8.9 million a year earlier, supported in part by closing a $4.1 million financing tranche linked to 50% enrollment in the NEPHRO CRRT study. The trial has enrolled 35 of 70 planned patients, with all 12 active sites able to recruit, and completion is expected in 2026. Talphera guided 2026 cash operating expenses to $17–18 million and scheduled a virtual investor and analyst day to discuss its business and clinical progress.